Moderna Stock Doubles, Adding $26.4 Billion After Cancer Vaccine Meets Both Phase 3 Goals
Moderna stock more than doubled at its premarket peak Wednesday after the company’s personalized mRNA cancer treatment, developed with Merck, succeeded in a pivotal Phase 3 melanoma trial. MRNA rose by approximately 105% from Tuesday’s $62.96 closing price, reaching an estimated peak near $129.07.
This content is automatically aggregated. Full credit goes to the original publisher (thecryptobasic.com).
